Related online content
Since work described herein is primarily unpublished, titles of presentations are referenced below to allow readers to view the recorded presentations posted on www.pmlconsortium.org.
Atwood W. Human polyoma virus receptor distribution. Session 1
Berger J. PML associated with neurologic therapies. Session 3
Buck C. Developing vaccines against JC polyomavirus. Session 4
Clifford D. PML treatment/IRIS. Session 4
DiMaio D. Cellular factors required for infection by small DNA viruses. Session 1
Enquist L. Axons, the front line sensors of alpha herpes virus PNS invasion. Session 1
Hirsch H. Testing JC and BK PyV antibody responses: why and how. Session 2
Imperiale M. Trafficking of BKPyV to the nucleus. Session 1
Legatie O. Biomarkers for JCV infection. Session 3
Lindberg R. Molecular markers for a PML risk in natalizumab treated MS patients. Session 3
Martin R. T cell immunity in PML and MS. Session 3
McGavern D. T cell surveillance of the acute and persistently infected brain. Session 2
Molloy E. PML associated with autoimmune and autoinflammatory diseases. Session 3
Nath A. Antisense to JCV. Session 4
Neu U. Polyomavirus structure, receptor interactions. Session 1
Olsson T. Host genetics in the control of JCV infection. Session 3
Ransohoff R. Blood brain barrier, CNS immune surveillance. Session 2
Schneider-Hohendorf T. Natalizumab treatment is associated with increased anti-JCV antibody seroconversion. Session 3
Shishido-Hara Y. JC viral inclusions in PML: PML-NBs. Session 2
Werner M. Host Abelson-kinase inhibitors. Session 4
Acknowledgments
The authors would like to acknowledge the Progressive Multifocal Leukoencephalopathy Consortium’s Board of Directors for its support of the research conference; the conference speakers and attendees who contributed to the discussions presented herein; Drs. Len Calabrese and Marianne Gerber, who also contributed to organization of the conference; and the PML Consortium Secretariat and AstraZeneca for their organizational support.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
AstraZeneca/MedImmune, Pfizer, and Roche are PML Consortium member companies. D. Pavlovic and M. Gerber are members of the PMLC Clinical Working Group. A. Patera, S. Butler, and R. Elston are members of the PMLC Research Working Group. Dejan Pavlovic and Andriani Patera are employees of MedImmune, the global biologics research and development arm of AstraZeneca, and own stock in AstraZeneca. Robert Elston and Marianne Gerber are employees of and own stock in F. Hoffmann-La Roche AG. Scott Butler and Anne Ryan are employees of and own stock in Pfizer Inc.
David B. Clifford, Robert L. Garcea, Eugene O. Major, Kenneth L. Tyler, and Thomas Weber are members of the PML Consortium Scientific Advisory Board. Kenneth Tyler has served as a scientific consultant or scientific advisory board member for Hoffman La Roche, Biogen, Genentech, Johnson & Johnson, and Pfizer.
Paola Cinque is a PML Consortium grantee and has received funding from the Consortium to support her research.
Ilse Peterson is an employee of Drinker Biddle & Reath, LLP, which serves as the PML Consortium Secretariat, and has no conflicts of interest to report.
Rights and permissions
About this article
Cite this article
Patera, A.C., Butler, S.L., Cinque, P. et al. 2nd International Conference on Progressive Multifocal Leukoencephalopathy (PML) 2015: JCV virology, progressive multifocal leukoencephalopathy pathogenesis, diagnosis and risk stratification, and new approaches to prevention and treatment. J. Neurovirol. 21, 702–705 (2015). https://doi.org/10.1007/s13365-015-0392-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13365-015-0392-5